Next Article in Journal
Flavin-Dependent Enzymes in Cancer Prevention
Next Article in Special Issue
Expression of Partitioning Defective 3 (Par-3) for Predicting Extrahepatic Metastasis and Survival with Hepatocellular Carcinoma
Previous Article in Journal
UVA Irradiation of Dysplastic Keratinocytes: Oxidative Damage versus Antioxidant Defense
Previous Article in Special Issue
The Role of Sox Genes in Lung Morphogenesis and Cancer
Int. J. Mol. Sci. 2012, 13(12), 16737-16750; doi:10.3390/ijms131216737
Article

Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer

1,2,†,* , 3,†
,
4
,
5
 and
2,*
1 Department of Biochemistry & Molecular Biology, College of Medical Science, Jishou University, Jishou 416000, China 2 Department of Biochemistry & Molecular Biology, Gannan Medical University, Ganzhou 341000, China 3 Hunan Provincial Key Laboratory for Biology and Control of Plant Diseases and Insect Pests, College of Bio-Safety Science & Technology, Hunan Agricultural University, Changsha 410128, China 4 Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming 650118, China 5 Clinical Laboratory, the First Affiliated Hospital, Gannan Medical University, Ganzhou 341000, China These authors contributed equally to this work.
* Authors to whom correspondence should be addressed.
Received: 28 September 2012 / Revised: 22 November 2012 / Accepted: 30 November 2012 / Published: 7 December 2012
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [510 KB, uploaded 19 June 2014]   |  

Abstract

Inhibitor of apoptosis protein-like protein-2 (ILP-2) has only been detected in the testis and in lymphoblastoid cells. Although previous studies have not reported the presence of ILP-2 in breast cancer tissues, this study indicates the presence of ILP-2 in breast cancer serum samples. To validate whether ILP-2 is a novel serological biomarker for breast cancer, we conducted two-dimensional gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization-time of flight mass spectrometry analysis on 400 breast cancer serum samples and 40 non-cancer serum samples (i.e., healthy controls). We then performed a Western blot analysis of 10 breast cancer serum samples and 10 non-cancer serum samples. Finally, we analyzed 35 serum samples from healthy controls or subjects with breast cancer, other types of cancer, galactophore hyperplasia or breast cancer post-surgery by using 2DE and enzyme-linked immunosorbent assay. Our results indicate that ILP-2 is a novel breast cancer biomarker in the peripheral blood.
Keywords: ILP-2; breast cancer; serological biomarker ILP-2; breast cancer; serological biomarker
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Xiang, M.; Zhou, W.; Gao, D.; Fang, X.; Liu, Q. Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer. Int. J. Mol. Sci. 2012, 13, 16737-16750.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert